Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.

Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA.

J Bone Miner Res. 2008 Jan;23(1):112-20.

2.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.

3.

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD.

Bone. 2003 Oct;33(4):522-32.

PMID:
14555255
4.

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.

J Bone Miner Res. 2008 Dec;23(12):1923-34. doi: 10.1359/jbmr.080710.

5.
6.

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Bone. 2009 Jun;44(6):1049-54. doi: 10.1016/j.bone.2009.02.014. Epub 2009 Feb 28.

PMID:
19254788
7.
8.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
9.

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD.

Arch Intern Med. 2002 May 27;162(10):1140-3.

PMID:
12020184
10.

Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.

Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E; Raloxifene Use for The Heart Trial Investigators.

J Natl Cancer Inst. 2008 Jun 18;100(12):854-61. doi: 10.1093/jnci/djn153. Epub 2008 Jun 10.

11.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10517716
12.

Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.

Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T; Women's Health Initiative Investigators.

J Bone Miner Res. 2006 Jun;21(6):817-28.

13.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

14.

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL.

Bone. 2007 Apr;40(4):843-51. Epub 2006 Dec 19.

PMID:
17182297
15.

Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL.

J Fam Pract. 2004 Oct;53(10):789-96. Erratum in: J Fam Pract. 2005 Mar;54(3):276.

PMID:
15469774
16.

Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women.

Finigan J, Greenfield DM, Blumsohn A, Hannon RA, Peel NF, Jiang G, Eastell R.

J Bone Miner Res. 2008 Jan;23(1):75-85.

17.

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R; Mulitple Outcomes of Raloxifene Evaluation Investigators.

J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17.

PMID:
12161484
18.

Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.

Siris E, Adachi JD, Lu Y, Fuerst T, Crans GG, Wong M, Harper KD, Genant HK.

Osteoporos Int. 2002 Nov;13(11):907-13.

PMID:
12415439
19.
20.
Items per page

Supplemental Content

Write to the Help Desk